Beyond Total Homocysteine: Context-Specific Biomarker Roles and Molecular Phenotypes Across Vascular and Neurological Disorders
Biomolecules · 11.11.2026 · 16 (11) · 1645
DOI: 10.3390/biom16111645 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 11.11.2026. Verfasst von Ayşegül Sümer und 2 weiteren Autor:innen. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Recep Tayyip Erdoğan University Development Foundation.
Abstract (Originalsprache)
Plasma total homocysteine (tHcy) is analytically mature, but its clinical meaning depends on the question the test is intended to answer. This narrative review interprets homocysteine as a context-specific biomarker using the FDA–NIH BEST (Biomarkers, EndpointS, and other Tools) framework, distinguishing susceptibility/risk, diagnostic, prognostic, monitoring, pharmacodynamic, and surrogate-endpoint uses, together with the pre-analytical, renal, nutritional, and pharmacological determinants of routine results. tHcy has established clinical utility as a diagnostic-pathway and monitoring marker in severe inherited homocysteine disorders. In vascular disease, stroke, and cognitive decline, it is a nonspecific susceptibility or prognostic marker, and in selected levodopa- or antiseizure-medication users, a candidate treatment-associated monitoring marker. It is not a diagnostic biomarker for Alzheimer’s or Parkinson’s disease, and reliable biochemical lowering by B vitamins has not translated consistently into clinical benefit, so it is not a qualified surrogate endpoint. We propose five molecular homocysteine phenotypes—remethylation-deficient, transsulfuration-deficient, renal-retention, treatment-related methylation, and protein-modification—as a hypothesis-generating conceptual framework that has not been empirically validated. Each phenotype is specified by routine measurements and exploratory analytes; S-adenosylmethionine, S-adenosylhomocysteine, homocysteine-thiolactone, and N-homocysteinylated proteins remain research tools. A tiered testing framework and a staged validation roadmap are proposed, both requiring prospective evaluation before clinical implementation.
Förderung
- Recep Tayyip Erdoğan University Development Foundation
Zitieren
APA
Sümer, A., Şahin, S., & Menteşe, A. (2026). Beyond Total Homocysteine: Context-Specific Biomarker Roles and Molecular Phenotypes Across Vascular and Neurological Disorders. Biomolecules, 16(11), 1645. https://doi.org/10.3390/biom16111645
Vancouver
Sümer A, Şahin S, Menteşe A. Beyond Total Homocysteine: Context-Specific Biomarker Roles and Molecular Phenotypes Across Vascular and Neurological Disorders. Biomolecules. 2026;16(11):1645. doi:10.3390/biom16111645
BibTeX
@article{Smer2026,
author = {Sümer, Ayşegül and Şahin, Sera and Menteşe, Ahmet},
title = {Beyond Total Homocysteine: Context-Specific Biomarker Roles and Molecular Phenotypes Across Vascular and Neurological Disorders},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {11},
pages = {1645},
doi = {10.3390/biom16111645}
}
EUVIMED